Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cue Biopharma, Inc.

0.7002
+0.00500.72%
Post-market: 0.6775-0.0227-3.24%16:34 EDT
Volume:72.34K
Turnover:49.88K
Market Cap:52.76M
PE:-1.08
High:0.7100
Open:0.6900
Low:0.6703
Close:0.6952
Loading ...

Cue Biopharma Inc - Common Stock and Warrants Sold at $0.79, Pre-Funded Warrants at $0.789

THOMSON REUTERS
·
15 Apr

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

THOMSON REUTERS
·
15 Apr

BRIEF-Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments

Reuters
·
15 Apr

Cue Biopharma Starts Underwritten Equity Offering

MT Newswires Live
·
15 Apr

Cue Biopharma announces common stock, warrant offering, no amount given

TIPRANKS
·
15 Apr

Cue Biopharma receives $12M upfront in CUE-501 license pact

TIPRANKS
·
15 Apr

Cue Biopharma Announces Proposed Public Offering

THOMSON REUTERS
·
15 Apr

Cue Biopharma Announces Proposed Public Offering

GlobeNewswire
·
15 Apr

Boehringer Ingelheim and Cue Biopharma Partner to Develop Treatment for Autoimmune and Inflammatory Diseases

THOMSON REUTERS
·
15 Apr

Cue Biopharma Inc: Co Is Also Eligible to Earn up to About $345 Mln in Milestone-Based Payments

THOMSON REUTERS
·
15 Apr

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire
·
15 Apr

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

GlobeNewswire
·
15 Apr

Cue Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
03 Apr

Cue Biopharma Price Target Maintained With a $2.00/Share by Citizens Capital Markets

Dow Jones
·
02 Apr

Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
02 Apr

Piper Sandler Sticks to Its Buy Rating for Cue Biopharma (CUE)

TIPRANKS
·
01 Apr

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
01 Apr

Cue Biopharma FY24 EPS ($0.72) Up From ($1.11) YoY; Revenue $9.287M Up From $5.490M YoY

Benzinga
·
01 Apr

Cue Biopharma, Inc. Q4 Basic EPS USD -0.13

THOMSON REUTERS
·
01 Apr

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

THOMSON REUTERS
·
01 Apr